Many Athersys, Inc.(ATHX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Athersys was Initiated by Needham on Feb 7, 2017 to Buy, Price Target of the shares are set at $7.
Company has reported several Insider transactions to the SEC, on Feb 1, 2017, Ismail Kola (director) purchased 15,000 shares at 1.01 per share price.On Feb 1, 2017, Jordan Davis (director) purchased 247,500 shares at 1.01 per share price.On Feb 1, 2017, Laura K Campbell (Senior Vice Pres Finance) purchased 20,000 shares at 1.01 per share price.
Athersys Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $-0.09. The company had revenue of $.31 million for the quarter, compared to analysts expectations of $.60 million. The companys revenue was down -21.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Athersys, Inc. (NASDAQ:ATHX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 2 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys.
Athersys, Inc. (NASDAQ:ATHX) shares are expected to touch $5.5 in the short term. This short term price target has been shared by 2 analysts. However, the standard deviation of short term price estimate has been valued at 4.95. The target price could hit $9 on the higher end and $2 on the lower end.
Tuesdays trading session turned out to be a no-profit no-loss event for Athersys, Inc. (NASDAQ:ATHX). The opening trade occurred at $1.21 and the highest and the lowest points of the day were $1.21 and $1.17 respectively. The final trade was registered at $1.2 and the volume by the end of the day had touched 585,360 shares. The 52-week high of the stock is $2.9 and the 52-week low is $1.02. According to the current valuation, the market cap of the company is $130 million and the total number of shares available in public circulation is 108,570,669.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The companys lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.